PFA ependymoma is among the deadliest childhood brain tumors. And for years, one of the most striking mysteries was this: boys get it more often, and do worse. Nobody knew why.
Now we do.
Thrilled to share our new paper in
@Nature : Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma
Using scRNA-seq from 26 primary PFA tumors, we found that male tumors are shifted toward a more stem-like, less differentiated state — with a striking enrichment of gliogenic progenitor-like cells. In other words: male PFA tumors appear developmentally “younger,” stalled earlier along the glial differentiation trajectory.
Then came the key mechanistic result.
Using the four-core genotype mouse model — which cleanly separates sex chromosome effects from gonadal hormone effects. The answer was not chromosomes. It was androgen signaling.
Androgens in the embryonic hindbrain delay glial differentiation, keeping progenitor cells immature for longer. That widens the developmental window for malignant transformation, offering a mechanistic explanation for both the male incidence bias and the worse outcomes.
Even more exciting: this biology is actionable.
The androgen receptor antagonist enzalutamide, already used in the clinic , and the AR degrader MTX-23 both suppressed PFA clonogenicity and growth. Other brain tumor subtypes were far less affected, suggesting this vulnerability may be unusually specific to PFA.
A deadly pediatric brain tumor.
A long-standing clinical mystery.
And now, a developmental and hormonal mechanism that points toward therapy.
Huge congratulations to co-first authors Jiao Zhang, Winnie Ong, and Alexandra Rasnitsyn, and to the entire international team from
@BCMHouston @TexasChildrens @McGillU @UPitt and many collaborators worldwide.
And a very special shoutout to Dr. Michael Taylor for leading this extraordinary project. Truly one of the best brain tumor researchers I know.
Paper:
nature.com/articles/s41586-0…